On January 6, 2026, Alumis Inc. announced that its treatment Envudeucitinib shows leading skin clearance compared to other therapies for plaque psoriasis in a Phase 3 program. This filing also includes an updated corporate presentation and is part of the company's strategy for regulatory submission later in 2026.